The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q3 2023 call → NOWe need answer YES/NO based on transcript. Need determine if management conveys recently finished expensive/heavy phase of major undertaking and now collecting, with results still reflecting paying phase not collecting. Transcript: Five Star Bancorp Q3 2023. They discuss expansion into Bay Area market with addition of seasoned team. Organic growth story continued. They added deposits. They mention "enhanced our expansion into the Bay Area market with an addition of another seasoned team of professionals." They have hired people. In Q&A: "recent expansion of the Bay Area. It looked like the teams there or the team there did $29 million of deposits in the third quarter... Are those mostly non-interest-bearing?" James: "Right now, as we sit here today, I think we've got about $38 million in deposits from our Bay Area folks... equally split... We expect that to be same or similar. From a lending perspective, I think we've got $5 million of credit book so far. A lot of it is C&I... As we move forward, we expect same and similar in terms of credit..." Later: "Where do you feel like you stand today? Is there a need in your mind to continue hiring or continue -- to continue building out the Bay Area? Or do you feel like you have what you need there in place already today? And then anywhere else across your footprint where you're seeing market opportunity? And what's your kind of appetite to incrementally hire from here?" James: "Well, we think we have a little ways to go in the Bay Area, Andrew. We're targeting probably four to five more people. When they come on, they may come on in January. And I think or maybe at least one will be coming on here before the end of the quarter. So we think with that team, we're going to be in very good shape in San Francisco Proper and the surrounds. Now there are several potential hires that are in the Bay Area, whether they'd be in the North Bay or in the East Bay that we've -- we're starting those dialogs. So ultimately, we could have upwards of 20 people in the Bay that are covering all aspects of that market down there. So we just have to see how time goes right now. Right now, we have nine people. And we've got some folks that are pretty near-term right now in terms of potential hires we've met with them several times.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.